Orphan Drugs Market Analyzed in New In-Demand Espicom Business Intelligence Report Available at MarketPublishers.com03 Jan 2013 • by Natalie Aster
LONDON – The worldwide market for orphan drugs was slightly over USD 49.5 billion in H2 2011. It grew by around one third in 2001-2011 given rapid development of the biological orphan drugs sector. Small biotech companies have recently been the market leaders. However, the trend changes due to the improving interest amid flagship pharmaceutical manufacturers.
At present, the number of rare diseases stands at around 6,800 and rises by almost 250 annually. The increasing governmental support together with promising commercial opportunities propels the industry. New drugs are continuously developed. In December 2012, for instance, a new drug for rare cholesterol disorder was approved by FDA. It is called Juxtapid. There are several orphan drugs already generating high profits. Imatinib and Tracleer are amid them.
New market research report “Orphan Drugs: Market Environment Products and Companies” developed by Espicom Business Intelligence draws up an elaborate picture of the world market for orphan drugs. The study offers an up-close look at the market environment, its challenges and opportunities. The report describes regulatory activity in top markets and activity of leading as well as emerging market participants. It provides valuable data on targeted diseases and examines innovative areas of research.
Orphan Drugs: Market Environment Products and Companies
Published: December, 2012
Price: US$ 1,390.00
More market research reports by the publisher can be found at Espicom Business Intelligence page.